Roubaix Capital LLC Buys 33,991 Shares of OrthoPediatrics Corp. $KIDS

Roubaix Capital LLC lifted its stake in OrthoPediatrics Corp. (NASDAQ:KIDS – Free Report) by 11.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 340,555 shares of the company’s stock after purchasing an additional 33,991 shares during the quarter. OrthoPediatrics comprises about 3.0% of Roubaix Capital LLC’s holdings, making the stock its 3rd largest holding. Roubaix Capital LLC owned 1.30% of OrthoPediatrics worth $7,584,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in OrthoPediatrics by 70.3% during the third quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock worth $26,000 after buying an additional 481 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of OrthoPediatrics in the 2nd quarter worth $34,000. Quantinno Capital Management LP acquired a new stake in shares of OrthoPediatrics in the 1st quarter worth $160,000. Waverly Advisors LLC purchased a new position in shares of OrthoPediatrics during the 1st quarter worth $184,000. Finally, Bank of America Corp DE purchased a new position in shares of OrthoPediatrics during the 2nd quarter worth $268,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Insider Transactions at OrthoPediatrics

In other news, major shareholder Squadron Capital Llc sold 302,369 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the insider directly owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David R. Pelizzon sold 302,369 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the director directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. 32.50% of the stock is currently owned by insiders.

OrthoPediatrics Price Performance

KIDS opened at $31.41 on Wednesday. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $34.53. The business has a 50 day simple moving average of $25.44 and a 200-day simple moving average of $20.44. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.55 and a quick ratio of 2.00.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. The firm had revenue of $72.66 million during the quarter, compared to analyst estimates of $68.50 million. On average, research analysts anticipate that OrthoPediatrics Corp. will post -1.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of OrthoPediatrics from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Needham & Company LLC restated a “buy” rating and set a $35.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, October 28th. Truist Financial boosted their target price on shares of OrthoPediatrics from $22.00 to $28.00 and gave the company a “hold” rating in a report on Wednesday, October 28th. Stifel Nicolaus raised their price target on shares of OrthoPediatrics from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, BTIG Research raised their price objective on OrthoPediatrics from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.75.

Read Our Latest Stock Analysis on KIDS

About OrthoPediatrics

(Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Featured Articles

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDS – Free Report).

Institutional Ownership by Quarter for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.